Literature DB >> 12183046

Role of N-methyl-D-aspartate receptors and the nitric oxide pathway in nociception/hyperalgesia elicited by protease-activated receptor-2 activation in mice and rats.

Atsufumi Kawabata1, Naoyuki Kawao, Hideki Itoh, Chiho Shimada, Kaori Takebe, Ryotaro Kuroda, Takashi Masuko, Kazuo Kataoka, Shinji Ogawa.   

Abstract

Activation of the peripheral protease-activated receptor-2 (PAR-2) triggers nociceptive behaviour and thermal hyperalgesia in rats. The present study created a novel mouse model for PAR-2-triggered nociception, and then examined the roles of NMDA receptors and the nitric oxide (NO) pathway in nociceptive processing by PAR-2. Intraplantar administration of the PAR-2 agonist SLIGRL-NH(2) elicited nociceptive responses in mice, an effect being more specific in mast cell-depleted mice. This PAR-2-triggered nociception was abolished by the NMDA receptor antagonist MK-801, but not the neuronal NO synthase inhibitor 7-nitro indazole. In contrast, the PAR-2-triggered thermal hyperalgesia in rats was blocked by both agents. Our study thus provides a novel mouse model for PAR-2-mediated nociception, and suggests that NMDA receptors are involved in PAR-2-triggered nociception and hyperalgesia, while NO contributes only to the latter.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12183046     DOI: 10.1016/s0304-3940(02)00702-4

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  2 in total

Review 1.  Diversification of PAR signaling through receptor crosstalk.

Authors:  Irene Lee-Rivera; Edith López; Ana María López-Colomé
Journal:  Cell Mol Biol Lett       Date:  2022-09-10       Impact factor: 8.702

2.  Brachystemma calycinum D. Don Effectively Reduces the Locomotor Disability in Dogs with Naturally Occurring Osteoarthritis: A Randomized Placebo-Controlled Trial.

Authors:  Maxim Moreau; Bertrand Lussier; Jean-Pierre Pelletier; Johanne Martel-Pelletier; Christian Bédard; Dominique Gauvin; Eric Troncy
Journal:  Evid Based Complement Alternat Med       Date:  2012-07-15       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.